The Latest Cardiac and Vascular News
– Unprecedented CLEAR Outcomes Study Approaching 95% MACE Accumulation– – U.S. Net Product Revenue of NEXLETOL® (bempedoic acid) Tablets and NEXLIZET® (bempedoic acid and ezetimibe) Tablets Grew approximately 109% Y/Y to $13.4 Million in the First Quarter 2022– – Retail Prescription Equivalents Grew 56.7% Year over Year – ANN ARBOR, Mich., May […]
Company is currently engaged in a strategic review process, evaluating additional development of its assets, collaborations and other strategic options WESTMINSTER, Colo., May 02, 2022 (GLOBE NEWSWIRE) — ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today reported first […]
First-Quarter 2022 Revenues of $25.7 Billion, Reflecting 82% Operational Growth; Excluding Contributions from Comirnaty(1) and Paxlovid, Revenues Increased 2% Operationally First-Quarter 2022 Reported Diluted EPS(2) of $1.37 and Adjusted Diluted EPS(3) of $1.62 Both Reported(2) and Adjusted(3) Diluted EPS Include a $0.05 Negative Impact for Acquired In-Process R&D Expenses(4), Which Prior to First-Quarter 2022 Had […]
New investment will progress treatment of pulmonary arterial hypertension (PAH), a rare condition which causes high blood pressure in the blood vessels that supply the lungs and can lead to heart failure. Current approved medications mainly address the symptoms of this rare condition. This novel approach aims to address the […]
The Financing round was led by growth equity firm Stripes, and marks Hello Heart’s leadership in cardiovascular digital therapeutics and proven ability to close gaps in heart health – the number one cause of death in the U.S. MENLO PARK, Calif.–(BUSINESS WIRE)–Hello Heart, the only digital therapeutic that focuses on […]
Former Google Health Executive to Expand Cardiovascular Strategy for Ocular Health Technology Company GUILFORD, Conn., April 28, 2022 — Tesseract Health, a health technology company developing a portable, non-invasive platform to detect health conditions through the eyes, proudly announces the appointment of Michael McConnell, MD, MSEE, as Tesseract’s Head of […]
Company looks to finalize development of its advanced interventional approach for heart failure management CAMPBELL, Calif., April 29, 2022 /PRNewswire/ — Adona Medical, a Shifamed portfolio company, announced today it has secured $37.5M Series B financing, which will be used to complete product development and support further evaluation of the company’s next-generation heart failure […]
Mesoblast Operational and Financial Highlights for Quarter Ended March 31, 2022 NEW YORK, April 28, 2022 (GLOBE NEWSWIRE) — Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an activity report for the third quarter ended March 31, 2022. Financial highlights Net cash usage […]
Reports First Quarter Revenues of $11.6 Billion, an Increase of 5% YoY; or 7% When Adjusted for Foreign Exchange Posts First Quarter Earnings Per Share of $0.59 and Non-GAAP EPS of $1.96; Includes Net Impact of ($0.10) per share for GAAP and Non-GAAP EPS Due to Acquired IPRD1 Charges Partially Offset […]
DANVERS, Mass. (AP) _ Abiomed Inc. (ABMD) on Thursday reported fiscal fourth-quarter net income of $60.3 million. The Danvers, Massachusetts-based company said it had profit of $1.31 per share. Earnings, adjusted for non-recurring gains and pretax gains, were $1.16 per share. The results exceeded Wall Street expectations. The average estimate […]
